FGF21 and metabolic dysfunction-associated steatohepatitis: Wong et al. demonstrated a two-step approach to improve the accuracy of diagnosing NASH using CK-18 and fibroblast growth factor 21, which reflected different aspects of the pathogenesis of NAFLD [48].